Fox Run Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Fox Run Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,673	Closed	-$358K	–	1036
2023 Q1	$358K	Buy	+26,673	New	+$461K	0.12%	351
2022 Q3	–	Sell	-11,216	Closed	-$155K	–	880
2022 Q2	$155K	Buy	+11,216	New	+$180K	0.08%	439
2019 Q3	–	Sell	-4,099	Closed	-$326K	–	608
2019 Q2	$326K	Buy	+4,099	New	+$367K	0.22%	195
2018 Q1	–	Sell	-19,786	Closed	-$1.16M	–	982
2017 Q4	$1.16M	Buy	19,786 +10,886	+122%	+$686K	0.34%	43
2017 Q3	$517K	Buy	8,900 +2,900	+48%	+$312K	0.15%	286
2017 Q2	$726K	Buy	6,000 +2,100	+54%	+$243K	0.25%	108
2017 Q1	$441K	Buy	+3,900	New	+$455K	0.18%	227

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Fox Run Management's ICPT Position: Q2 2023 in Review

Fox Run Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 26,673 shares — an estimated $358K sold.

Fox Run Management first reported a position in ICPT in Q1 2017 and held it in 7 quarters. The position peaked at $1.16M in Q4 2017. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Fox Run Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Fox Run Management sold 26,673 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $358K.
Fox Run Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Fox Run Management's Intercept Pharmaceuticals, Inc. position peaked at $1.16M in Q4 2017.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Fox Run Management's 13F filing for Q2 2023, filed 11 Aug 2023.